Does the change in serum soluble ST2 levels predict subsequent mortality or transplantation in patients with severe chronic NYHA class III to IV heart failure?
Serum soluble ST2 is identified as a novel biomarker whose changes independently predict mortality or transplantation in severe heart failure.
Serum soluble ST2 is a novel biomarker for neurohormonal activation in patients with heart failure. In patients with severe chronic NYHA class III to IV heart failure, the change in ST2 levels is an independent predictor of subsequent mortality or transplantation.
Weinberg et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: